510(k) device
Nerivio, FGD000075-4.7
Theranica Bioelectronics , Ltd. · Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT, Class II) · First FDA decision Jan 22, 2021, newest Jan 22, 2021Migraine and headache
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Nerivio FGD000075-4.7"
MAUDE reports
0
Brand "Nerivio FGD000075-4.7", since 2015
PubMed studies
0
Mentioning "Nerivio FGD000075-4.7"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Nerivio, FGD000075-4.7
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Nerivio, FGD000075-4.7510(k)
K203181 · Decided Jan 22, 2021 · 88 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative PainNational determinationOn the books10.2Updated Dec 2, 2024
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
- Transcutaneous Electrical Nerve Stimulation for Chronic Low Back PainNational analysisReview closedCAG-00429NUpdated Sep 24, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (CLBP)National determinationOn the books160.27Updated Feb 10, 2026
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Nerivio FGD000075-4.7", any status and sponsor, newest update first.
No registered device study names "Nerivio FGD000075-4.7".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Nerivio FGD000075-4.7", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QGT
7 reports: 3 malfunction, 3 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Nerivio FGD000075-4.7"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QGT.
- NerivioTheranica Bio-Electronics, Ltd. · 510(k) 2025
- NerivioInfinityTheranica Bioelectronics , Ltd. · 510(k) 2023
- NerivioTheranica Bioelectronics , Ltd. · 510(k) 2023
- Nerivio MigraTheranica Bioelectronics , Ltd. · De Novo 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.